Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
Status:
Completed
Trial end date:
2018-01-06
Target enrollment:
Participant gender:
Summary
The patient was given a daily dose of apatinib 500mg (or based on weight). Individualized
chemotherapy regimens were given based on molecular expression and prior chemotherapy.